Related Experiment Video
Updated: Jun 6, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment
Faiz Anwer1, Tommy Lan2, Michael Dolph2
1Hematology, Oncology, Multiple Myeloma, Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA.
Aims:
Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).
Materials & Methods:
A systematic literature review was performed via searches of databases and relevant conference proceedings. Both simulated treatment comparison (STC) and matching-adjusted indirect comparison (MAIC) were used to adjust for between-trial differences.
Results:
Seven randomized controlled trials were identified, five of which were subsequently excluded from the indirect treatment comparison during feasibility assessment. A consistent OS benefit was observed for DPd vs. DKd and DVd for patients with RRMM, using both STC and MAIC methods.
Conclusions:
The findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM.
More Related Videos
13:12Nitroreductase/Metronidazole-Mediated Ablation and a MATLAB Platform RpEGEN for Studying Regeneration of the Zebrafish Retinal Pigment Epithelium
Published on: March 2, 2022
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Comparing the Survival Analysis of Two or More Groups
Relative Risk